Literature DB >> 22373032

Intrastromal femtosecond laser presbyopia correction: 1-year results of a multicenter study.

Mike P Holzer1, Michael C Knorz, Mark Tomalla, Tobias M Neuhann, Gerd U Auffarth.   

Abstract

PURPOSE: To investigate functional outcomes of the INTRACOR femtosecond laser-based intrastromal procedure to treat presbyopia.
METHODS: Sixty-three eyes from 63 presbyopic patients (median age: 54 years) with mild hyperopia were enrolled in this prospective, ethics committee-approved, multi-center, nonrandomized clinical trial. The INTRACOR procedure was performed using the Technolas femtosecond laser (Technolas Perfect Vision GmbH) in the nondominant eye. Postoperatively, follow-up was performed at 1 day, 1 week, and 1, 3, 6, and 12 months and included near and distance visual acuity tests, slit-lamp examinations, and corneal topography.
RESULTS: All 63 surgeries were uneventful. Twelve months postoperatively, outcomes of 58 (92.1%) eyes were available for evaluation. Median uncorrected distance visual acuity (0.1 logMAR [range: 0.5 to 0.0 preoperatively and 0.5 to -0.1 postoperatively]) and corrected distance visual acuity (CDVA) (0.0 logMAR [range: 0.2 to -0.2 preoperatively and 0.3 to -0.1 postoperatively]) remained stable. Median spherical equivalent changed from +0.63 diopters (D) preoperatively to 0.00 D postoperatively. Median uncorrected near visual acuity increased significantly from 0.7 logMAR (range: 1.0 to 0.2) preoperatively to 0.2 logMAR (range: 0.8 to -0.1) postoperatively and eyes gained a median of 4 lines (range: 1 to 9 lines). Losses of 2 lines of CDVA were noted in 7.1% of eyes. Ring cuts were faintly visible at 12 months.
CONCLUSIONS: The INTRACOR presbyopia procedure showed good and stable visual acuity outcomes over 12-month follow-up but loss of CDVA occurred in 7% of eyes. Overall patient satisfaction with the procedure was approximately 80%. Short treatment time and maintained corneal surface integrity are advantages of this procedure. Copyright 2012, SLACK Incorporated.

Entities:  

Mesh:

Year:  2012        PMID: 22373032     DOI: 10.3928/1081597X-20120203-01

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  9 in total

1.  [Current state of refractive surgery of the cornea and lens].

Authors:  M C Knorz
Journal:  Ophthalmologe       Date:  2013-07       Impact factor: 1.059

2.  [Intrastromal femtosecond laser-based presbyopia correction].

Authors:  M P Holzer
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

3.  Assessment of contrast sensitivity loss after intrastromal femtosecond laser and LASIK procedure.

Authors:  Elsa L C Mai; Ie-Bin Lian; David C K Chang
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

4.  [Effect of intrastromal correction of presbyopia with femtosecond laser (INTRACOR) on mesopic contrast sensitivity].

Authors:  A Fitting; N Menassa; G U Auffarth; M P Holzer
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

5.  A Novel Concept of Correcting Presbyopia: First Clinical Results with a Phakic Diffractive Intraocular Lens.

Authors:  Ruediger Schmid; Holger Luedtke
Journal:  Clin Ophthalmol       Date:  2020-07-17

6.  [Functional results after bilateral intrastromal femtosecond laser correction of presbyopia].

Authors:  R Khoramnia; M P Holzer; A Fitting; G U Auffarth; T M Rabsilber
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

Review 7.  Corneal Refractive Procedures for the Treatment of Presbyopia.

Authors:  Kareem Moussa; Naz Jehangir; Tova Mannis; Wai L Wong; Majid Moshirfar
Journal:  Open Ophthalmol J       Date:  2017-04-27

Review 8.  Presbyopic correction on the cornea.

Authors:  Samuel Arba Mosquera; Jorge L Alió
Journal:  Eye Vis (Lond)       Date:  2014-11-13

Review 9.  Advances in femtosecond laser technology.

Authors:  Thais Pinheiro Callou; Renato Garcia; Adriana Mukai; Natalia T Giacomin; Rodrigo Guimarães de Souza; Samir J Bechara
Journal:  Clin Ophthalmol       Date:  2016-04-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.